Multicenter clinical study of immune-cell therapy in patients with malignant tumors.
Phase 1
Recruiting
- Conditions
- malignant tumor
- Registration Number
- JPRN-jRCTc030190256
- Lead Sponsor
- Goto Shigenori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6000
Inclusion Criteria
(1)Diagnostic imaging or Pathological diagnosis of malignant tumor.
(2)Informed consent has been obtained.
Exclusion Criteria
(1)HIV Ab positive.
(2)T cell- or NK cell-originated leukemia and/or lymphoma.(LAK therapy)
(3)Patients who have previously treated allogenic transplantation.
(4)Responsible doctors judged the patient inappropriate for the clinical study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method